Clinical Trial Update: Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating irinotecan and bevacizumab with temozolomide in refractory/relapsed CNS tumors; trial completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Johns Hopkins All Children's Hospital | Conditions: Central Nervous System Tumors | Phase 1 | Status: COMPLETED | Results posted: 2019-08-08